CN104302627A - 用于治疗癌症的嘧啶化合物 - Google Patents
用于治疗癌症的嘧啶化合物 Download PDFInfo
- Publication number
- CN104302627A CN104302627A CN201380025291.3A CN201380025291A CN104302627A CN 104302627 A CN104302627 A CN 104302627A CN 201380025291 A CN201380025291 A CN 201380025291A CN 104302627 A CN104302627 A CN 104302627A
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- cancer
- group
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 20
- 201000011510 cancer Diseases 0.000 title claims description 20
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 106
- 239000000203 mixture Substances 0.000 claims abstract description 51
- 238000000034 method Methods 0.000 claims abstract description 30
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 12
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 4
- -1 hetercycloalkylalkyl Chemical group 0.000 claims description 84
- 125000000217 alkyl group Chemical group 0.000 claims description 69
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 63
- 150000003839 salts Chemical class 0.000 claims description 41
- 125000003118 aryl group Chemical group 0.000 claims description 37
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 26
- 238000002360 preparation method Methods 0.000 claims description 24
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 7
- 125000001188 haloalkyl group Chemical group 0.000 claims description 7
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000005936 piperidyl group Chemical group 0.000 claims description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 3
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 3
- 125000001118 alkylidene group Chemical group 0.000 claims description 3
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 208000025113 myeloid leukemia Diseases 0.000 claims description 3
- 201000000498 stomach carcinoma Diseases 0.000 claims description 3
- 208000012991 uterine carcinoma Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract description 3
- 229910052757 nitrogen Chemical group 0.000 abstract description 2
- 229910052717 sulfur Chemical group 0.000 abstract description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 239000002585 base Substances 0.000 description 58
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 238000005481 NMR spectroscopy Methods 0.000 description 24
- 125000003342 alkenyl group Chemical group 0.000 description 21
- 125000000304 alkynyl group Chemical group 0.000 description 21
- 235000019439 ethyl acetate Nutrition 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 239000011734 sodium Substances 0.000 description 16
- 239000012044 organic layer Substances 0.000 description 15
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 238000001035 drying Methods 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 11
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 125000000623 heterocyclic group Chemical group 0.000 description 8
- 150000001721 carbon Chemical group 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 7
- 229940124530 sulfonamide Drugs 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 5
- 239000004327 boric acid Substances 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 101150003085 Pdcl gene Proteins 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 125000004442 acylamino group Chemical group 0.000 description 3
- 125000004423 acyloxy group Chemical group 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000002906 microbiologic effect Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- XNMQEEKYCVKGBD-UHFFFAOYSA-N 2-butyne Chemical compound CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000006323 alkenyl amino group Chemical group 0.000 description 2
- 125000003302 alkenyloxy group Chemical group 0.000 description 2
- 125000004171 alkoxy aryl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 125000006319 alkynyl amino group Chemical group 0.000 description 2
- 125000005133 alkynyloxy group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 2
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 125000004992 haloalkylamino group Chemical group 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 2
- 125000004309 pyranyl group Chemical class O1C(C=CC=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 150000005837 radical ions Chemical class 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000009834 vaporization Methods 0.000 description 2
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
- XTJLXXCARCJVPJ-TWTPFVCWSA-N (2e,4e)-hepta-2,4-diene Chemical compound CC\C=C\C=C\C XTJLXXCARCJVPJ-TWTPFVCWSA-N 0.000 description 1
- LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- HPARLNRMYDSBNO-UHFFFAOYSA-N 1,4-benzodioxine Chemical compound C1=CC=C2OC=COC2=C1 HPARLNRMYDSBNO-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- PZZOEXPDTYIBPI-UHFFFAOYSA-N 2-[[2-(4-hydroxyphenyl)ethylamino]methyl]-3,4-dihydro-2H-naphthalen-1-one Chemical compound C1=CC(O)=CC=C1CCNCC1C(=O)C2=CC=CC=C2CC1 PZZOEXPDTYIBPI-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- JLUZCHOYSPEHES-UHFFFAOYSA-N 3-aminocyclobutan-1-ol Chemical compound NC1CC(O)C1 JLUZCHOYSPEHES-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 1
- GUUULVAMQJLDSY-UHFFFAOYSA-N 4,5-dihydro-1,2-thiazole Chemical compound C1CC=NS1 GUUULVAMQJLDSY-UHFFFAOYSA-N 0.000 description 1
- WEDKTMOIKOKBSH-UHFFFAOYSA-N 4,5-dihydrothiadiazole Chemical compound C1CN=NS1 WEDKTMOIKOKBSH-UHFFFAOYSA-N 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- OKUUXORYPHTTRK-UHFFFAOYSA-N O=S(c(cn1)ccc1Cl)N1CCOCC1 Chemical compound O=S(c(cn1)ccc1Cl)N1CCOCC1 OKUUXORYPHTTRK-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 125000005631 S-sulfonamido group Chemical group 0.000 description 1
- XRARZTFVERRJFX-UHFFFAOYSA-N S1CC=CC2=C1C=CC=N2.N2=CC=CC=C2 Chemical compound S1CC=CC2=C1C=CC=N2.N2=CC=CC=C2 XRARZTFVERRJFX-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000004948 alkyl aryl alkyl group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001768 cations Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical class N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- JCWIWBWXCVGEAN-UHFFFAOYSA-L cyclopentyl(diphenyl)phosphane;dichloropalladium;iron Chemical compound [Fe].Cl[Pd]Cl.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1 JCWIWBWXCVGEAN-UHFFFAOYSA-L 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- OBISXEJSEGNNKL-UHFFFAOYSA-N dinitrogen-n-sulfide Chemical compound [N-]=[N+]=S OBISXEJSEGNNKL-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229950004385 flunamine Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229940089256 fungistat Drugs 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 208000027700 hepatic dysfunction Diseases 0.000 description 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000003010 ionic group Chemical group 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- KDGKTJGPFXIBEB-UHFFFAOYSA-N n-hydroxyformamide Chemical compound ONC=O KDGKTJGPFXIBEB-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- HMRCBLAEVOMPHP-UHFFFAOYSA-N oxadiazole quinoline Chemical compound C1=CON=N1.N1=CC=CC2=CC=CC=C21 HMRCBLAEVOMPHP-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- CFHIDWOYWUOIHU-UHFFFAOYSA-N oxomethyl Chemical compound O=[CH] CFHIDWOYWUOIHU-UHFFFAOYSA-N 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003009 phosphonic acids Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical class C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 229940093916 potassium phosphate Drugs 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- IIVUJUOJERNGQX-UHFFFAOYSA-N pyrimidine-5-carboxylic acid Chemical compound OC(=O)C1=CN=CN=C1 IIVUJUOJERNGQX-UHFFFAOYSA-N 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- MSXHSNHNTORCAW-GGLLEASOSA-M sodium;(2s,3s,4s,5r,6s)-3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].O[C@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O MSXHSNHNTORCAW-GGLLEASOSA-M 0.000 description 1
- NGSFWBMYFKHRBD-UHFFFAOYSA-N sodium;2-hydroxypropanoic acid Chemical compound [Na+].CC(O)C(O)=O NGSFWBMYFKHRBD-UHFFFAOYSA-N 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- 125000004962 sulfoxyl group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- WGLLSSPDPJPLOR-UHFFFAOYSA-N tetramethylethylene Natural products CC(C)=C(C)C WGLLSSPDPJPLOR-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 150000004867 thiadiazoles Chemical class 0.000 description 1
- RLTPJVKHGBFGQA-UHFFFAOYSA-N thiadiazolidine Chemical compound C1CSNN1 RLTPJVKHGBFGQA-UHFFFAOYSA-N 0.000 description 1
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 235000019263 trisodium citrate Nutrition 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
本发明公开了式I或II的化合物:或
Description
相关申请
本申请与2011年5月12日提交的PCT申请PCT/US2011/036215和2012年10月01日提交的PCT/US2012/058298有关。
发明领域
本发明涉及化合物、组合物和治疗癌症的方法。
发明背景
急性成淋巴细胞性白血病(ALL)是儿童中最常见的恶性肿瘤,常见类型在75%-85%的病例中通过化疗可治愈。总的来说,每年,更不常见的T细胞和罕见的B细胞亚型出现小于2000个病例,因此可以归类为罕见的疾病;这些亚型预后较差。不幸地是,无论哪种亚型,对治疗的抗性和复发都是儿科癌症死亡的主要原因。另外,ALL化疗可以引起较晚的并发症,其在儿科幸存人群中日益被认识到。实际上,在儿科癌症生存者中,直接与治疗有关的严重迟发效应(神经认知后遗症、听觉并发症、心血管功能障碍、胃肠/肝功能失常、生长迟缓、继发性恶性肿瘤和不育症)的发病率为约25%。更好地了解治疗抗性及其逆转不仅有助于复发的患者,而且有助于降低ALL患者所需化疗的剂量,从而降低对于未来生存者的长期毒性。
发明简述
本发明的第一个方面为式I或II的活性化合物:
其中∶
环A为5-或6-元杂芳基基团(例如,吡啶基、嘧啶基、噻唑基、呋喃基、哒嗪基、吡嗪基、咪唑基等)。虚线为任选的双键。X为N或O。Y为环A中任何合适位置的碳原子或S或N杂原子。
R1为–R5R6,其中R5为共价键、C1至C3烷基或连接基基团(例如,磺酰胺、醚、酯、胺、酰胺等),和R6为环烷基、杂环烷基、芳基、杂芳基、烷基环烷基、烷基杂环烷基、烷基芳基、烷基杂芳基或烷基,且其中R6任选地被独立选择的极性基团取代一次、两次或三次;
R2为–R7R8,其中R7为共价键或C1至C3烷基,且R8为环烷基、杂环烷基、芳基、杂芳基或烷基,且其中R8任选地用独立选择的极性基团取代一次、两次或三次;
R3选自H、烷基、芳基、芳基烷基、环烷基烷基、杂环烷基烷基、杂芳基烷基和烷氧基烷基,其中每个任选地用独立选择的极性基团取代一次、两次或三次;
R4为H、低级烷基、卤素或低级烷氧基;
或其药学上可接受盐。
本发明的另一个方面是在药学上可接受载体中如本文所述的活性化合物。
本发明的另一个方面是在有需要的受试者中治疗癌症的方法,其包括向所述受试者给药治疗癌症的有效量的如本文所述的活性化合物。
本发明的另一个方面是用于治疗癌症和/或用于制备治疗癌症的药物的如本文所述的活性化合物。
优选的实施方案的详细说明
如本文中单独使用或作为另一个基团的部分使用的“烷基”指含有1到10个碳原子的直链或支链烃基。烷基的代表性实例包括,但不限于甲基、乙基、正丙基、异丙基、正丁基、仲丁基、异丁基、叔丁基、正戊基、异戊基、新戊基、正己基、3-甲基己基、2,2-二甲基戊基、2,3-二甲基戊基、正庚基、正辛基、正壬基、正癸基等。如本文使用的“低级烷基”是烷基的子集,在一些实施方案中是优选的,并且指包含1至4个碳原子的直链或支链烃基。低级烷基的代表性的实例包括,但不限于甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基等。除非另有说明,否则术语“烷基”或“低级烷基”包括取代的和未取代的烷基或低级烷基,并且这些基团可以被选自下述的基团取代:卤素(例如,卤代烷基)、烷基、卤代烷基、链烯基、炔基、环烷基、环烷基烷基、芳基、芳基烷基、杂环基、杂环烷基、羟基、烷氧基(从而产生聚烷氧基比如聚乙二醇)、链烯基氧基、炔基氧基、卤代烷氧基、环烷氧基、环烷基烷氧基、芳氧基、芳基烷氧基、杂环氧基、杂环基烷氧基、巯基、烷基-S(O)m、卤代烷基-S(O)m、链烯基-S(O)m、炔基-S(O)m、环烷基-S(O)m、环烷基烷基-S(O)m、芳基-S(O)m、芳基烷基-S(O)m、杂环基-S(O)m、杂环基烷基-S(O)m、氨基、羧基、烷基氨基、链烯基氨基、炔基氨基、卤代烷基氨基、环烷基氨基、环烷基烷基氨基、芳基氨基、芳基烷基氨基、杂环氨基、杂环烷基氨基、二取代的-氨基、酰基氨基、酰氧基、酯、酰胺、磺酰胺、脲、烷氧基酰基氨基、氨基酰氧基、硝基或氰基,其中m=0、1、2或3。
如本文中单独使用或作为另一个基团的部分使用的“链烯基”指包含1至10个碳原子(或在“低级链烯基”中,1至4个碳原子)的直链或支链烃基,其在正链中包括1至4个双键。链烯基的代表性实例包括,但不限于乙烯基、2-丙烯基、3-丁烯基、2-丁烯基、4-戊烯基、3-戊烯基、2-己烯基、3-己烯基、2,4-庚二烯等。除非另有说明,否则术语“链烯基”或“低级链烯基”旨在包括取代的和未取代的链烯基或低级链烯基,这些基团可以被如对于上述烷基或低级烷基所描述的基团取代。
如本文单独或作为另一个基团的部分使用的“炔基”指包含1至10个碳原子(或在“低级炔基”中,1至4个碳原子)的直链或支链烃基,其在正链中包括1个三键。炔基的代表性实例包括,但不限于2-丙炔基、3-丁炔基、2-丁炔基、4-戊炔基、3-戊炔基等。除非另有说明,否则术语“炔基”或“低级炔基”旨在包括取代的和未取代的炔基或低级炔基,这些基团可以被与对于上述烷基或低级烷基所述相同的基团取代。
如本文中单独使用或作为另一个基团的部分使用的“环烷基”指包含3、4或5至6、7或8个碳的饱和的或部分不饱和的环烃基(其中杂环基中碳可以如下讨论的被取代)。环烷基的代表性实例包括环丙基、环丁基、环戊基、环己基、环庚基和环辛基。这些环可以任选地被如本文所述的另外的取代基(比如卤素或低级烷基)取代。除非另有说明,否则术语“环烷基”是上位的,旨在包括如下讨论的杂环基。
如本文中单独使用或作为另一个基团的部分使用的“杂环基”或“杂环”指脂肪族(例如,完全或部分饱和的杂环)或芳香族(例如杂芳基)单环或双环环系。单环环系的示例为包含1、2、3或4个独立地选自氧、氮和硫的杂原子的任何5元或6元环。5元环具有0-2个双键,6元环具有0-3个双键。单环环系的代表性实例包括,但不限于氮杂环丁烷、氮杂氮丙啶、二氮杂1,3-二氧戊环、二噁烷、二噻烷、呋喃、咪唑、咪唑啉、咪唑烷、异噻唑、异噻唑啉、异噻唑烷、异噁唑、异噁唑啉、异噁唑烷、吗啉、噁二唑、噁二唑啉、噁二唑烷、噁唑、噁唑啉、噁唑烷、哌嗪、哌啶、吡喃、吡嗪、吡唑、吡唑啉、吡唑烷、吡啶、嘧啶、哒嗪、吡咯、吡咯啉、吡咯烷、四氢呋喃、四氢噻吩、四嗪、四唑、噻二唑、噻二唑啉、噻二唑烷、噻唑、噻唑啉、噻唑烷、噻吩、硫代吗啉、硫代吗啉砜、噻喃、三嗪、三唑、三噻烷等。双环环系的示例为与如本文定义的芳基基团、如本文定义的环烷基基团、或如本文定义的另一个单环环系稠合的任何上述单环环系。双环环系的代表性实例包括,但不限于例如苯并咪唑、苯并噻唑、苯并噻二唑、苯并噻吩、苯并噁二唑、苯并噁唑、苯并呋喃、苯并吡喃、苯并噻喃、苯并二噁烯(benzodioxine)、1,3-苯并间二氧杂环戊烯、噌啉、吲唑、吲哚、二氢吲哚、吲嗪、二氮杂萘、异苯并呋喃、异苯并噻吩、异吲哚、异二氢吲哚、异喹啉、酞嗪、嘌呤、吡喃并吡啶、喹啉、喹嗪、喹喔啉、喹唑啉、四氢异喹啉、四氢喹啉、噻喃并吡啶(thiopyranopyridine)等。这些环包括其季铵化衍生物,并且可以任选地被选自下述的基团取代:卤素、烷基、卤代烷基、链烯基、炔基、环烷基、环烷基烷基、芳基、芳基烷基、杂环基、杂环烷基、羟基、烷氧基、链烯基氧基、炔基氧基、卤代烷氧基、环烷氧基、环烷基烷氧基、芳氧基、芳基烷氧基、杂环基氧基、杂环烷氧基、巯基、烷基-S(O)m、卤代烷基-S(O)m、链烯基-S(O)m、炔基-S(O)m、环烷基-S(O)m、环烷基烷基-S(O)m、芳基-S(O)m、芳基烷基-S(O)m、杂环基-S(O)m、杂环烷基-S(O)m、氨基、烷基氨基、链烯基氨基、炔基氨基、卤代烷基氨基、环烷基氨基、环烷基烷基氨基、芳基氨基、芳基烷基氨基、杂环氨基、杂环烷基氨基、二取代的-氨基、酰基氨基、酰氧基、酯、酰胺、磺酰胺、脲、烷氧基酰基氨基、氨基酰氧基、硝基或氰基,其中m=0、1、2或3。
如本文中单独使用或作为另一个基团的部分使用的“芳基”指单环碳环环体系或具有一个或多个芳香环的双环碳环稠环体系。芳基的代表性的实例包括薁基、茚满基、茚基、萘基、苯基、四氢萘基等。除非另有说明,否则术语“芳基”旨在包括取代的和未取代的芳基,这些基团可以被与如对于上述烷基或低级烷基所述相同的基团取代。
如本文中单独使用或作为另一个基团的部分使用的“芳基烷基”指通过如本文定义的烷基连接到母体分子部分的如本文定义的芳基。芳基烷基的代表性实例包括,但不限于苄基、2-苯基乙基、3-苯基丙基、2-萘-2-基乙基等。
如本文使用的“杂芳基”为如对于上述杂环所述的。
如本文中单独使用或作为另一个基团的部分使用的“烷氧基”指通过氧基-O-连接到母体分子部分的如本文定义的烷基或低级烷基(因此,包括取代的形式比如聚烷氧基)。烷氧基的代表性实例包括,但不限于甲氧基、乙氧基、丙氧基、2-丙氧基、丁氧基、叔丁氧基、戊氧基、己氧基等。
如本文使用的“卤素”指任何合适的卤素,包括-F、-Cl、-Br和-I。
如本文使用的“巯基”指-SH基团。
如本文使用的“叠氮基”指-N3基团。
如本文使用的“氰基”指-CN基团。
如本文使用的“甲酰基”指-C(O)H基团。
如本文使用的“羧酸”指-C(O)OH基团。
如本文使用的“羟基”指-OH基团。
如本文使用的“硝基”指-NO2基团。
如本文中单独使用或作为另一个基团的部分使用的“酰基”指-C(O)R基团,其中R为任何合适的取代基比如芳基、烷基、链烯基、炔基、环烷基或如本文描述的其它合适的取代基。
如本文中单独使用或作为另一个基团的部分使用的“烷硫基”指通过如本文定义的硫代部分连接到母体分子部分的如本文定义的烷基。烷硫基的代表性实例包括,但不限于甲硫基、乙硫基、叔丁硫基、己硫基等。
如本文使用的“氨基”指基团-NH2。
如本文中单独使用或作为另一个基团的部分使用的“烷基氨基”指基团-NHR,其中R为烷基。
如本文中单独使用或作为另一个基团的部分使用的“芳基烷基氨基”指基团-NHR,其中R为芳基烷基。
如本文中单独使用或作为另一个基团的部分使用的“二取代的-氨基”指基团-NRaRb,其中Ra和Rb独立地选自烷基、卤代烷基、链烯基、炔基、环烷基、环烷基烷基、芳基、芳基烷基、杂环基、杂环烷基。
如本文中单独使用或作为另一个基团的部分使用的“酰基氨基”指基团-NRaRb,其中Ra为如本文定义的酰基,Rb选自氢、烷基、卤代烷基、链烯基、炔基、环烷基、环烷基烷基、芳基、芳基烷基、杂环基、杂环烷基。
如本文中单独使用或作为另一个基团的部分使用的“酰氧基”指基团-OR,其中R为如本文定义的酰基。
如本文中单独使用或作为另一个基团的部分使用的“酯”指-C(O)OR基团,其中R为任何合适的取代基比如烷基、环烷基、链烯基、炔基或芳基。
如本文中单独使用或作为另一个基团的部分使用的“酰胺”指-C(O)NRaRb基团,其中Ra和Rb为任何合适的取代基,比如烷基、环烷基、链烯基、炔基或芳基。
如本文使用的“亚磺酰基(sulfoxyl)”指式-S(O)R的化合物,其中R为任何合适的取代基,比如烷基、环烷基、链烯基、炔基或芳基。
如本文使用的“磺酰基”指式-S(O)(O)R的化合物,其中R为任何合适的取代基,比如氨基、烷基、环烷基、链烯基、炔基或芳基。
如本文使用的“磺酸酯”指式-S(O)(O)OR的化合物,其中R为任何合适的取代基,比如烷基、环烷基、链烯基、炔基或芳基。
如本文使用的“磺酸”指式-S(O)(O)OH的化合物。
如本文中单独使用或作为另一个基团的部分使用的“磺酰胺”指-S(O)2NRaRb基团,其中Ra和Rb为任何合适的取代基,比如H、烷基、环烷基、链烯基、炔基或芳基。
如本文中单独使用或作为另一个基团的部分使用的“脲”指-N(Rc)C(O)NRaRb基团,其中Ra、Rb和Rc为任何合适的取代基,比如H、烷基、环烷基、链烯基、炔基或芳基。
如本文单独或作为另一个基团的部分使用的“烷氧基酰基氨基”指–N(Ra)C(O)ORb基团,其中Ra、Rb为任何合适的取代基,比如H、烷基、环烷基、链烯基、炔基或芳基。
如本文单独或作为另一个基团的部分使用的“氨基酰氧基”指–OC(O)NRaRb基团,其中Ra和Rb为任何合适的取代基,比如H、烷基、环烷基、链烯基、炔基或芳基。
如本文使用的“极性基团”指其中彼此共价键合形成基团的原子的核没有同等地共享结合它们的共价键的电子的基团;即在一个原子周围的电子云比另一个原子的更密集。这导致共价键的一端为相对负性,另一端为相对正性;即,存在一个负极和正极。极性基团的实例包括,不限于卤素、羟基、烷氧基、羧基、硝基、氰基、氨基(伯、仲和叔)、酰氨基、脲基、亚磺酰氨基(sulfonamido)、亚磺酰基、巯基、甲硅烷基、S-亚磺酰氨基、N-亚磺酰氨基、C-羧基、O-羧基、C-酰胺基、N-酰胺基、磺酰基、N-叔-丁氧基羰基(或“t-BOC”)基、膦酰基(phosphono)、吗啉代、哌嗪基、四唑基等。参见例如美国专利No.6,878,733,以及醇、硫醇、聚乙二醇、多元醇(包括糖、氨基糖、糖醛酸)、磺酰胺、甲酰胺、酰肼、N-羟基甲酰胺、脲、金属螯合物(包括大环配体或冠醚金属螯合物)。极性基团可以是离子基团。
如本文使用的“离子基”包括阴离子基团和阳离子基团,包括以一种形式不带电荷但是可以容易地转化为离子基(例如,通过在水溶液中质子化或去质子化)的基团(有时,称为“可离子化(ionogenic)”基团)。实例包括,但不限于羧酸酯、磺酸酯、磷酸酯、胺、N-氧化物和铵(包括季铵化的杂环胺,比如咪唑鎓和吡啶鎓)基团。参见,例如美国专利No.6,478,863、6,800,276和6,896,246。另外的实例包括糖醛酸、羧酸、磺酸、胺,和诸如胍鎓、磷酸、膦酸、磷脂酰胆碱、磷鎓、硼酸酯、硫酸酯等的部分。
如本文中单独使用或作为另一个基团的部分使用的“氘”指安全、非放射性的氢同位素。上述基团或取代基中的任何氢都可以被氘替代,以提供“氘代”化合物,在一些实施方案中以修饰/改善代谢稳定性,得到更好的安全性、耐受性和/或功效。
如本文中使用的“连接基基团”或“连接基团”通常是二价芳香族、脂肪族或混合芳香族或脂肪族的基团。因此,连接基团包括直链或支链的、取代或未取代的芳基、烷基、烷基芳基、或烷基芳基烷基连接基团,其中所述烷基基团是饱和的或不饱和的,并且其中所述烷基和芳基基团任选地含有独立选择的杂原子,比如1、2、3或4个选自N、O和S的杂原子。在一些实施方案中,优选含有2-5个、10个或20个碳原子的较短的连接基团,其带有任意如上文所述的杂原子。合适的连接基团的大量实例是已知的,包括但不限于在美国专利No.8,247,572、8,097,609、6,624,317、6,613,345、6,596,935和6,420377中所描述的那些,这些专利的公开内容通过引证的方式整体纳入本文。
如本文使用的“治疗”指赋予罹患疾病的患者益处的任何类型的治疗,所述益处包括改善患者的病症(例如,一个或多个症状)、延迟疾病发展、延迟疾病发病等。
如本文使用的“药学上可接受”指所述化合物或组合物适于给药至受试者,以获得本文所述的治疗,而不会在疾病的严重性和治疗的必要性方面具有过度有害副作用。
本发明的活性化合物可以任选地连同用于治疗癌症的其它化合物一起给药。其它化合物可以任选地共同地给药。如本文使用的术语“共同地”指时间足够接近以产生组合效应(即,共同地可以是同时地,或者其可以是在短时间之内彼此前后进行两个或多个事件)。
本发明主要涉及治疗人类受试者,但是本发明也可以在动物受试者,特别是哺乳动物受试者中进行,比如小鼠、大鼠、狗、猫、家畜和马,以用于兽医目的和用于药物筛选和药物研发目的。受试者可以是任何年龄,包括婴儿、少年(juvenile)、青年(adolescent)、成年人和老年人受试者。
1.活性化合物
如上所述,本发明提供式I或II的活性化合物或其药学上可接受盐:
其中:
环A为5-或6-元杂芳基基团(例如,吡啶基、嘧啶基、噻唑基、呋喃基、哒嗪基、吡嗪基、咪唑基等)。虚线为任选的双键。X为N或O。Y为环A中任何合适位置的碳原子或S或N杂原子。
R1为-R5R6,其中R5为共价键、C1至C3烷基或连接基基团(例如,磺酰胺、醚、酯、胺、酰胺等),和R6为环烷基、杂环烷基、芳基、杂芳基、烷基环烷基、烷基杂环烷基、烷基芳基、烷基杂芳基或烷基,和其中R6任选地被独立选择的极性基团取代一次、两次或三次;
R2为-R7R8,其中R7为共价键或C1至C3烷基,且R8为环烷基、杂环烷基、芳基、杂芳基或烷基,其中R8为任选地被独立选择的极性基团取代一次、两次或三次;
R3选自H、烷基、芳基、芳基烷基;环烷基烷基、杂环烷基烷基、杂芳基烷基、和烷氧基烷基,其中每个任选地被独立选择的极性基团取代一次、两次或三次;
R4为H、低级烷基、卤素或低级烷氧基。
在前述的一些实施方案中,R5为共价键;在其它实施方案中,R5为C1至C3亚烷基,比如–CH2-,或R5为连接基基团(例如,磺酰胺、酰胺等)。
在前述的一些实施方案中,R7为共价键;在其它实施方案中,R7为C1至C3亚烷基,比如–CH2-。
在一些实施方案中,R6为苯基、哌啶基或C1-C8烷基、或C3至C8环烷基,其中苯基、哌啶基、烷基或环烷基烷基为未取代的或被磺酰基、卤素、氨基、硝基、烷基、烷氧基、卤代烷基、环烷基、杂环烷基、芳基或杂芳基取代1至3次。
在其中R8为C1-C8烷基或环己基的一些实施方案中,所述烷基或环己基为未取代的或被羟基或氨基取代1至3次。
在一些实施方案中,R3为C1-C8烷基、C3-C8环烷基、C4-C12环烷基烷基、C3-C8杂环烷基、C4-C12杂环烷基烷基、C4-C12芳基烷基、C4-C12杂芳基烷基,其中每个为未取代的或被羟基、卤素或烷氧基取代1至3次。
在一些实施方案中,R4为H。
前述的具体实例包括,但不限于∶
包括其药学上可接受盐。
本发明的化合物的更具体的实例包括,但不限于下表1-8中列出的那些。
如上所述,本文公开的活性化合物可以以其药学上可接受盐的形式提供。药学上可接受盐是保留了母体化合物所期望的生物活性,而不赋予不期望的毒性作用的盐。这样的盐的实例是(a)与无机酸形成的酸加成盐,所述无机酸为例如盐酸、氢溴酸、硫酸、磷酸、硝酸等;和与有机酸形成的盐,所述有机酸为比如例如乙酸、草酸、酒石酸、琥珀酸、马来酸、富马酸、葡糖酸、柠檬酸、苹果酸、抗坏血酸、苯甲酸、鞣酸、棕榈酸、藻酸、聚谷氨酸、萘磺酸、甲烷磺酸、对甲苯磺酸、萘二磺酸、聚半乳糖醛酸等;(b)与元素的阴离子比如氯、溴和碘形成的盐,和(c)衍生自碱的盐,比如铵盐,碱金属盐比如钠和钾盐;碱土金属盐比如钙和镁盐,和与有机碱比如二环己胺和N-甲基-D-葡糖胺形成的盐。
如本文所述的活性化合物可以根据已知的方法或对本领域技术人员明显的变化方案来制备。
2.药物制剂
根据已知技术,可以将上述活性化合物配制在药物载体中用于给药。参见例如Remington,The Science And Practice of Pharmacy(9th Ed.1995)。在根据本发明的药物制剂的制备中,通常将活性化合物(包括其生理学上可接受的盐)与例如可接受的载体混合。当然,载体必须在与制剂中的任何其它成分相容的意义上讲是可接受的,且必须对患者无害。载体可以为固体或液体,或二者,优选与所述化合物配制为单位剂量制剂,例如片剂,其可以包含0.01或0.5重量%至95重量%或99重量%的活性化合物。可以将一种或多种活性化合物掺入本发明的制剂中,可以通过任何熟知的药学技术制备该制剂,包括混合各组分,任选包括一种或多种辅助成分。
本发明的制剂包括适用于口服、直肠、局部、口颊(例如舌下)、阴道、肠胃外(例如皮下、肌内、皮内或静脉内)、局部(即皮肤和粘膜表面,包括气道表面)、经皮给药、和室内注射(注射到脑室,例如通过植入导管或omman储库,比如在病态肥胖的情况下)的制剂,但是在任何给定情况下,最合适的途径主要取决于所治疗病症的性质和严重性,以及所使用的具体活性化合物的性质。
适用于口服给药的制剂可以以下述单位形式存在,比如胶囊、扁囊剂、锭剂或片剂,各自包含预定量的活性化合物;粉末或颗粒剂;水或非水液体中的溶液剂或混悬剂;或水包油型或油包水型乳剂。这样的制剂可以通过任何合适的药物方法制备,所述方法包括使活性化合物和合适的载体(其可以包含一种或多种如上所述辅助成分)混合的步骤。通常,本发明的制剂可以通过将活性化合物与液体或细粉碎的固体载体或二者均匀和紧密混合,然后(如有必要)使得到的混合物进行成形来制备。例如,可以通过将包含活性化合物的粉末或颗粒,任选与一种或多种辅助成分一起压制或模制来制备片剂。可以通过在合适的机器中,将任选与粘合剂、润滑剂、惰性稀释剂和/或表面活性剂/分散剂混合的自由流动形式比如粉末或颗粒的化合物压制,制备压制片剂。可以通过在合适的机器中,将用惰性液体粘合剂润湿的粉末化的化合物塑模来制备模制片剂。
适用于口颊(舌下)给药的制剂包括锭剂(lozenge),其包括在矫味基质中的活性化合物,矫味基质通常为蔗糖和阿拉伯胶或黄蓍胶;和锭剂(pastille),其包含在惰性基质中的所述化合物,惰性基质为比如明胶和甘油,或蔗糖和阿拉伯胶。
适于肠胃外给药的本发明的制剂包括活性化合物的无菌水和非水注射液,这类制剂优选地与预定接受者的血液等渗。这些制剂可以包含抗氧剂、缓冲剂、抑菌剂和使制剂与预定接受者的血液等渗的溶质。水和非水无菌混悬剂可以包括助悬剂和增稠剂。制剂可以存在于单位/剂量或多剂量容器中,例如密封安瓿和小瓶中,并且可以在冷冻干燥(冻干)条件下贮存,临用前只需要加入无菌液体载体,例如盐水或注射用水。临时注射液和混悬液可以由前述类型的无菌粉末、颗粒和片剂制备。例如,在本发明的一个方面,提供在密封容器中的单位剂量形式的可注射的、稳定的无菌组合物,其包括式(I)化合物或其盐。所述化合物或盐以冻干形式提供,其能够用合适的药学上可接受载体重构,形成适于将其注射到受试者的液体组合物。单位剂量形式通常包括约10mg至约10g化合物或盐。当化合物或盐基本上是水不溶性时,可以使用足量的生理上可接受的乳化剂,其量足以使化合物或盐在水性载体中乳化。一种这样有用的乳化剂是磷脂酰胆碱。
适于直肠给药的制剂优选地以单位剂量栓剂存在。这些可以通过使活性化合物与一种或多种常规固体载体例如可可脂混合,然后使得到的混合物成形来制备。
适于局部施用至皮肤上的制剂优选地采用软膏剂、霜剂、洗剂、糊剂、凝胶剂、喷雾剂、气雾剂或油的形式。可以使用的载体包括凡士林、羊毛脂、聚乙二醇、醇、经皮促进剂及其两种或多种的组合。
适用于经皮给药的制剂可以呈适合保持与接受者的表皮长时间紧密接触的贴剂存在。适用于经皮给药的制剂也可以通过离子电渗疗法(参见例如Pharmaceutical Research 3(6):318(1986))递送,通常采取活性化合物的任选缓冲的水性溶液形式。合适的制剂包括柠檬酸盐或bis/tris缓冲液(pH6)或乙醇/水,并且包含0.1至0.2M的活性成分。
进一步,本发明提供本文公开的化合物及其盐的脂质体制剂。用于形成脂质体混悬剂的技术是本领域熟知的。当化合物或其盐为水溶性盐时,使用常规脂质体技术,可以将化合物及其盐掺入脂质囊中。在这种情况下,由于化合物或盐的水溶性,化合物或盐基本上包裹在脂质体的亲水性中心或核内。使用的脂质层可以具有任何常规组成,并且可以包含胆固醇或可以不含胆固醇。当感兴趣的化合物或盐为水不溶性时,还使用常规脂质体形成技术,盐可基本上包裹在形成脂质体结构的疏水性脂质双层中。在任一种情况下,如通过使用标准声处理技术和均质化技术,可以减小制备的脂质体的大小。
当然,可以将包含本文公开的化合物或其盐的脂质体制剂冻干,得到冻干物,其可以用药学上可接受载体比如水重构,再生脂质体混悬液。
可以由本文公开的水不溶性化合物或其盐制备其它药物组合物,比如水性基质(aqueous base)乳剂。在这种情况下,组合物将包含足量的药学上可接受乳化剂,使需要量的化合物或其盐乳化。特别有用的乳化剂包括磷脂酰胆碱和卵磷脂。
除了式(I)的化合物或其盐之外,药物组合物还可以包含其它添加剂,比如pH调节添加剂。特别地,有用的pH-调节剂包括酸比如盐酸、碱或缓冲剂,比如乳酸钠、乙酸钠、磷酸钠、柠檬酸钠、硼酸钠或葡糖酸钠。另外,组合物可以包含微生物防腐剂。有用的微生物防腐剂包括尼泊金甲酯、尼泊金丙酯和苯甲醇。当制剂被置于设计用于多次剂量使用的小瓶中时,通常使用微生物防腐剂。当然,如所指出的,可以使用本领域中熟知的技术将本发明的药用组合物冻干。
3.剂量和给药途径
如上所述,本发明提供药物制剂,其包括在药学上可接受载体中的活性化合物(包括其药学上可接受盐),用于口服、直肠、局部、口颊、肠胃外、肌内、皮内或静脉内和经皮给药。
任何具体化合物的治疗有效剂量(其用法在本发明范围内)将在化合物与化合物之间、患者与患者之间有些变化,并会取决于患者的病症和递送途径。一般而言,约0.1至约50mg/kg的剂量具有治疗功效,所有重量均基于活性化合物的重量计算(包括使用盐的情况)。在高水平下有关的毒性可限制静脉内剂量至较低水平,比如至多约10mg/kg,所有重量均均基于活性基础的重量计算(包括使用盐的情况)。对于口服给药,可以使用约10mg/kg至约50mg/kg的剂量。在一些实施方案中,对于肌肉注射,可以使用约0.5mg/kg至5mg/kg的剂量。在一些实施方案中,对于静脉内或口服给药,化合物的剂量为1μmol/kg至50μmol/kg,更优选22μmol/kg至33μmol/kg。治疗持续时间可以为每日1次,持续两至三周时间,或直至病症被基本上控制。
活性化合物可以以药学上可接受前药提供,其为本发明的活性化合物的前药以及本发明的化合物的两性离子形式(可能时),所述前药是在合理的医学判断范围内适用于与人类和低等动物的组织接触,而不会有过度毒性、刺激、过敏反应等,与合理风险/益处比相称,且对于它们的预期用途有效。术语“前药”指在体内快速转化(例如通过血液中水解)得到上式母体化合物的化合物。详细讨论提供在T.Higuchi和V.Stella,Prodrugs as Novel delivery Systems,Vol.14of the A.C.S.SymposiumSeries and in Edward B.Roche,ed.,Bioreversible Carriers in Drug Design,American Pharmaceutical Association and Pergamon Press,1987中,这两篇都通过引用并入本文。也参见美国专利No.6,680,299。实例包括在受试者体内代谢成具有如本文所述活性化合物的活性的活性药物的前药,其中所述前药为醇或羧酸基(如果这样的基团存在于化合物中)的酯;醇基(如果这样的基团存在于化合物中)的缩醛或缩酮;胺基(如果这样的基团存在于化合物中)的N-曼尼希碱或亚胺;或羰基(如果这样的基团存在于化合物中)的席夫碱、肟、缩醛、烯醇酯、噁唑烷、或噻唑烷,比如在美国专利No.6,680,324和美国专利No.6,680,322中描述的。
如上所述,本文描述的活性化合物可用于治疗癌症。本发明的化合物和方法可治疗癌症的实例包括,但不限于髓性白血病、成淋巴细胞性白血病、黑素瘤、乳腺癌、肺癌、结肠癌、肝癌、胃癌、肾癌、卵巢癌、子宫癌和脑癌。
在下述非限制性实例中,更详细地解释本发明。
实施例1-7
通式结构I:
实施例1
2-(丁基氨基)-4-(((1r,4r)-4-羟基环己基)氨基)-N-(4-(吗啉代-磺酰基)
苯基)嘧啶-5-甲酰胺
通用方法A:
2,4-二氯-N-(4-(吗啉代-磺酰基)苯基)嘧啶-5-甲酰胺
在0℃下,向2,4-二氯嘧啶-5-甲酰氯(422mg,2.0mmol)的二氯甲烷(10mL)溶液中加入4-(吗啉代-磺酰基)苯胺(508mg,2.1mmol)和DIEA(387mg,3.0mmol)。将得到的混合物在0℃下搅拌1小时。然后,加入水。用EtOAc(3x)萃取得到的混合物。将合并的有机层干燥(Na2SO4),过滤并浓缩。在ISCO上纯化剩余物,得到呈白色固体的标题化合物(701.2mg,84%)。1H NMR(400MHz,DMSO-d6)δ11.98–11.90(m,1H),8.29(d,J=6.4Hz,1H),7.89(d,J=8.8Hz,2H),7.69(d,J=8.8Hz,2H),3.65–3.56(m,4H),2.87–2.78(m,4H);MS m/z 418.30[M+H]+。
2-氯-4-(((1r,4r)-4-羟基环己基)氨基)-N-(4-(吗啉代-磺酰基)苯基)嘧
啶-5-甲酰胺
在0℃下,向2,4-二氯-N-(4-(吗啉代-磺酰基)苯基)嘧啶-5-甲酰胺(700mg,1.68mmol)的IPA(15mL)溶液中加入反式-4-氨基环己醇(231.4mg,2.2mmol)和DIEA(387mg,3.0mmol)。在0℃下,搅拌得到的混合物50分钟,温热至室温,并再搅拌50分钟。然后,除去溶剂,将剩余物溶于DCM和甲醇(20mL,3:2,v/v)的混合物中,使悬浮液过滤通过滤纸,得到呈白色固体的标题化合物(683.4mg,82%)。1H NMR(400MHz,DMSO-d6)δ10.71(s,1H),8.69(s,1H),7.96–7.89(m,2H),7.76–7.70(m,2H),4.57(s,1H),3.93–3.81(m,1H),3.64–3.57(m,4H),3.49–3.40(m,1H),2.88–2.78(m,4H),1.95–1.86(m,2H),1.85–1.76(m,2H),1.38–1.20(m,4H);MS m/z 496.20[M+H]+。
2-(丁基氨基)-4-(((1r,4r)-4-羟基环己基)氨基)-N-(4-(吗啉代-磺酰基)
苯基)嘧啶-5-甲酰胺
在室温下,向2-氯-4-(((1r,4r)-4-羟基环己基)氨基)-N-(4-(吗啉代-磺酰基)苯基)嘧啶-5-甲酰胺(86mg,0.17mmol)的IPA(10mL)溶液中加入丁胺(59.6mg,0.81mmol)和DIEA(124.7mg,0.96mmol)。在室温下,搅拌得到的混合物3小时。然后,加入水。得到的混合物用EtOAc(3X)萃取。将合并的有机层干燥(Na2SO4),过滤并浓缩。在ISCO上纯化剩余物,得到呈白色固体的标题化合物(59.3mg,64%)。1H NMR(400MHz,CD3OD+CDCl3)δ8.21(s,1H),7.71–7.64(m,2H),7.59–7.53(m,2H),3.93–3.77(m,1H),3.74–3.64(m,4H),3.63–3.58(m,4H),3.56–3.46(m,1H),3.26(t,J=7.1Hz,2H),2.91–2.81(m,4H),2.05–1.95(m,2H),1.93–1.82(m,2H),1.50–1.41(m,2H),1.33–1.17(m,6H),0.83(t,J=7.3Hz,3H);13C NMR(101MHz,CD3OD+CDCl3)δ166.8,156.4,143.5,128.8,128.6,120.3,120.2,69.2,66.0,45.9,41.0,33.4,31.6,30.2,20.0,13.7;MS m/z 533.30[M+H]+。
表1描述了使用合适的试剂,按照在实施例1中描述的方法(通用方法A)制备的化合物。(注:Mer IC50:++++指<10nM;+++指介于10-100nM之间,++指介于100nM-1μM之间;+指介于1-30μM之间;-指无活性)。
实施例2
2-(丁基氨基)-N-(4-氟苄基)-4-(((反式)-4-羟基环己基)氨基)嘧啶-5-
甲酰胺
通用方法B:
2-(丁基氨基)-4-(((反式)-4-羟基环己基)氨基)嘧啶-5-甲酸甲酯
在0℃下,向2,4-二氯嘧啶-5-甲酰氯(500mg,2.38mmol)的二氯甲烷(30mL)溶液中加入甲醇(87.6mg,2.73mmol)和二异丙基乙胺(369mg,2.86mmol)。在0℃下,搅拌得到的混合物1小时。然后,除去溶剂。将剩余物(461mg,94%)溶于IPA(20mL)中,接着加入反式-4-氨基环己醇(301.6mg,2.62mmol),然后滴加DIEA(461.4mg,3.57mmol)。在0℃下,搅拌得到的混合物90分钟。在向其中加入丁胺(208.8mg,2.86mmol),接着加入DIEA(461.4mg,3.57mmol)。在室温下,搅拌得到的混合物3小时。然后,加入水。用EtOAc(3X)萃取得到的混合物。将合并的有机层干燥(Na2SO4),过滤并浓缩。在ISCO上纯化剩余物,得到2-(丁基氨基)-4-(((反式-4-羟基环己基)氨基)嘧啶-5-甲酸甲酯(682.6mg,经3步89%)。1H NMR(400MHz,CDCl3)δ9.21(s,1H),8.77(s,1H),6.29(s,1H),4.81–4.64(m,1H),4.51(s,3H),4.46-4.38(m,1H),4.13-4.11(m,2H),2.89-2.81(m,2H),2.74(d,J=9.7Hz,2H),2.35–2.25(m,2H),2.23–2.00(m,6H),1.67(t,J=7.2Hz,3H);13C NMR(101MHz,CDCl3)δ167.9,162.5,161.3,160.3,95.5,69.7,51.2,48.3,41.1,33.8,31.7,30.3,20.1,13.8;MS m/z 323.20[M+H]+。
2-(丁基氨基)-N-(4-氟苄基)-4-(((反式)-4-羟基环己基)氨基)嘧啶-5-
甲酰胺
将2-(丁基氨基)-4-(((反式-4-羟基环己基)氨基)嘧啶-5-甲酸甲酯(682.6mg,2.12mmol)和氢氧化锂一水合物(888.4mg,21.2mmol)在甲醇和水(25mL,3:2,v/v)混合物中的混合物加热回流2小时。然后,将反应混合物冷却至室温,并通过4.0N的HCl(4N)溶液酸化至PH 3。用EtOAc(4x)萃取得到的混合物。将合并的有机层干燥(Na2SO4)并浓缩,得到2-(丁基氨基)-4-(((1r,4r)-4-羟基环己基)氨基)嘧啶-5-甲酸(647.1mg,99%),其直接用于下一步中而没有进一步纯化。MS m/z 309.30[M+H]+。
在室温下,向所述酸(61mg,0.20mmol)、O-(苯并三唑-1-基)-N,N,N′,N′-四甲基脲四氟硼酸盐(TBTU,81.4mg,0.25mmol,1.3eq)和N,N-二异丙基乙胺(DIEA,77.5mg,0.60mmol,3.0eq)的无水DMF(3.0mL)溶液中滴加在DMF(1.0mL)中的4-氟苄胺(37.5mg,0.30mmol,1.5eq)。将得到的混合物搅拌过夜,然后用EtOAc(15mL)稀释,并用水(3x)洗涤。将有机层干燥(Na2SO4)并浓缩。在HPLC上纯化剩余物,得到呈黄色固体的标题化合物(61.5mg,74%)。1H NMR(400MHz,CDCl3)δ9.57(d,J=7.4Hz,1H),8.77(s,1H),8.13(s,1H),7.40–7.31(m,1H),7.29–7.22(m,3H),7.00(t,J=8.6Hz,2H),4.44(d,J=5.2Hz,2H),4.00(s,1H),3.77–3.62(m,1H),3.40(dd,J=13.0,6.9Hz,2H),2.15–2.09(m,2H),2.04(d,J=7.6Hz,2H),1.66–1.54(m,2H),1.49–1.33(m,6H),0.94(t,J=7.3Hz,3H);MS m/z 416.30[M+H]+。
表2描述了使用合适的试剂,按照在实施例2中描述的方法(通用方法B)制备的化合物
实施例3
(1r,4r)-4-((2-(丁基氨基)-5-(5-(吗啉代-磺酰基)吡啶-2-基)嘧啶-4-基)
氨基)环己醇
通用方法C:
4-((6-氯代吡啶-3-基)磺酰基)吗啉
在0℃下,向2-氯吡啶-5-磺酰氯(212mg,1.0mmol)的DCM(10mL)溶液中加入吗啉(87.1mg,1.0mmol)。在0℃下,搅拌得到的混合物10分钟,然后滴加DIEA(194mg,1.5mmol)。在0℃下,搅拌该混合物2小时。然后,用EtOAc(15mL)稀释该混合物,并用水(2x)洗涤。将有机层干燥(Na2SO4),过滤并浓缩。在ISCO上纯化剩余物,得到呈白色固体的标题化合物(246.1mg,94%)。1H NMR(400MHz,CDCl3)δ8.73–8.65(m,1H),7.94(dd,J=8.3,2.5Hz,1H),7.49(dd,J=8.3,0.6Hz,1H),3.74–3.63(m,4H),2.99(dd,J=5.6,3.9Hz,4H);13C NMR(101MHz,cdcl3)δ155.9,148.7,137.9,131.1,124.9,65.9,45.8;MS m/z 263.30[M+H]+。
(1r,4r)-4-((2-(丁基氨基)-5-(5-(吗啉代-磺酰基)吡啶-2-基)嘧啶-4-基)
氨基)环己醇
向10mL的微波管中装入2,4-二氯嘧啶-5-硼酸频哪醇酯(55mg,0.20mmol)、K2CO3(41.5mg,0.30mmol)和THF(2.0mL)。然后,在微波照射下,将得到的混合物加热至80℃并持续15分钟。之后,顺序加入4-((6-氯吡啶-3-基)磺酰基)吗啉(52.5mg,0.20mmol)、Pd(PPh3)4(23.1mg,0.02mmol)、K2CO3(41.5mg,0.30mmol)、丁胺(116.8mg,1.60mmol)和水(0.5mL)。在微波照射下,将得到的混合物加热至150℃并持续30分钟。将该混合物用EtOAc(15mL)稀释,并用水(2x)洗涤。将有机层干燥(Na2SO4)、过滤并浓缩。在ISCO和HPLC上纯化剩余物,得到呈白色固体的标题化合物(27.4mg,28%)和(1r,4r)-4-((2-(丁基氨基)嘧啶-4-基)氨基)环己醇(25.7mg,49%)。1H NMR(400MHz,CDCl3)δ10.65(d,J=7.1Hz,1H),9.46(t,J=5.4Hz,1H),8.87(d,J=2.2Hz,1H),8.31(s,1H),8.10(dd,J=8.6,2.3Hz,1H),7.77(d,J=8.7Hz,1H),4.19–4.09(m,1H),3.84–3.68(m,5H),3.51–3.44(m,2H),3.15–3.06(m,4H),2.86–2.66(m,3H),2.28–2.15(m,2H),2.13–2.01(m,2H),1.72–1.61(m,2H),1.56–1.36(m,6H),0.96(t,J=7.4Hz,3H);13C NMR(101MHz,CDCl3)δ159.4,156.9,153.1,146.6,142.8,136.8,130.2,118.9,103.4,69.2,66.0,49.7,45.8,41.3,33.3,31.0,29.5,20.1,13.7;MS m/z 491.30[M+H]+。
表3描述了使用合适的试剂,按照在实施例3中描述的方法(通用方法C)制备的化合物。
实施例4
反式-4-((2-(丁基氨基)-5-(5-氟代吡啶-2-基)嘧啶-4-基)氨基)环己醇
和
反式-4-((2-(丁基氨基)-5-(5-((4-甲基哌嗪-1-基)甲基)呋喃-2-基)嘧啶
-4-基)氨基)环己醇
通用方法D:
反式4-((5-溴-2-(丁基氨基)嘧啶-4-基)氨基)环己醇
向5-溴-2,4-二氯嘧啶(34.2g,150mmol)和4-氨基环己醇(17.3g,150mmol)的i-PrOH(300mL)溶液中加入DIPEA(39.2mL,225mmol)。搅拌反应混合物12小时。然后,在减压下蒸发溶剂,之后将剩余物再溶于EtOAc中,并用盐水洗涤。将有机层干燥(Na2SO4)并浓缩,得到4-((5-溴-2-氯嘧啶-4-基)氨基)环己醇(46g,150mmol),使用其而无需进一步纯化。
向4-((5-溴-2-氯嘧啶-4-基)氨基)环己醇(46g,150mmol)的甲苯(150mL)溶液中加入正丁胺(150mL,1.5mol)。在80℃下,加热该反应混合物12小时。然后,在减压下蒸发溶剂,之后将剩余物再溶于EtOAc中,并用盐水洗涤。将有机层干燥(Na2SO4)并浓缩,得到反式-4-((5-溴-2-(丁基氨基)嘧啶-4-基)氨基)环己醇(47.5g,92%)。1H NMR(400MHz,CDCl3)δ7.82(s,1H),5.01–4.80(m,2H),3.97–3.82(m,1H),3.65(tt,J=10.4,4.2Hz,1H),3.31(dt,J=7.1,6.1Hz,2H),2.21(s,1H),2.16–2.06(m,2H),2.06–1.95(m,2H),1.59–1.49(m,2H),1.49–1.34(m,4H),1.34–1.20(m,2H),0.92(t,J=7.3Hz,3H);13C NMR(101MHz,CDCl3)δ161.14(s),157.59(s),155.72(s),69.70(s),48.85(s),41.39(s),33.94(s),31.84(s),30.62(s),20.12(s),13.86(s).MS m/z 343.0[M+1]+。
反式-4-((2-(丁基氨基)-5-(5-氟吡啶-2-基)嘧啶-4-基)氨基)环己醇
在对空气开放情况下,在120℃下加热(5-氟吡啶-2-基)三羟基硼酸锂(99mg,0.60mmol)、溴化铜(3.0mg,0.020mmol)、碳酸钾(83.0mg,0.60mmol)、4-((5-溴-2-(丁基氨基)嘧啶-4-基)氨基)环己醇(68.7mg,0.20mmol)和PdCl2(dppf)(8.2mg,0.010mmol)在DMF和H2O(2.0mL/0.5mL)的混合物中的混合物30分钟,然后使其冷却至室温。通过过滤穿过薄的硅藻土垫料(用DMF洗涤)除去不溶性物质。然后,在减压下除去溶剂,并在ISCO上纯化剩余物,得到反式-4-((2-(丁基氨基)-5-(5-氟吡啶-2-基)嘧啶-4-基)氨基)环己醇(UNC2861A)(46mg,65%)。1H NMR(400MHz,CD3OD)δ8.54(d,J=3.0Hz,1H),8.26(s,1H),7.93(dd,J=9.0,4.1Hz,1H),7.80–7.71(m,1H),4.20–4.05(m,1H),3.67(td,J=10.0,5.1Hz,1H),3.48(s,2H),2.16(d,J=8.5Hz,2H),2.05–1.92(m,2H),1.67(dt,J=12.6,7.5Hz,2H),1.59–1.38(m,6H),1.00(t,J=7.4Hz,3H).LC-MS(ESI+):tR=4.481min,MS m/z 360.0[M+1]+。
5-(2-(丁基氨基)-4-((反式-4-羟基环己基)氨基)嘧啶-5-基)呋喃-2-甲
醛
使在丁醇(2.5mL)中的乙酸钯(II)(2.9mg,0.013mmol)、磷酸钾(186.8mg,0.88mmol)、反式-4-((5-溴-2-(丁基氨基)嘧啶-4-基)氨基)环己醇(150mg,0.44mmol)、SPhos(9.1mg,0.022mmol)和(5-甲酰基呋喃-2-基)硼酸(92.3mg,0.66mmol)的混合物脱气,并在N2气氛下加热和在10ml微波管中于150℃下微波照射20分钟。用水稀释得到的混合物,并用EtOAc(3x)萃取。将合并的有机层干燥(Na2SO4)并浓缩。在HPLC上纯化剩余物以提供5-(2-(丁基氨基)-4-((反式-4-羟基环己基)氨基)嘧啶-5-基)呋喃-2-甲醛(50.1mg,32%)。1H NMR(400MHz,cdcl3)δ9.49(s,1H),8.22(s,1H),7.28(d,J=3.8Hz,1H),6.55(d,J=3.8Hz,1H),5.25–5.07(m,1H),4.13–3.98(m,1H),3.79–3.70(m,1H),3.41(dd,J=13.3,6.9Hz,2H),2.25–2.15(m,2H),2.10–2.01(m,2H),1.79–1.68(m,1H),1.65–1.55(m,2H),1.54–1.34(m,5H),0.95(t,J=7.3Hz,3H);13CNMR(101MHz,cdcl3)δ175.1,161.9,158.9,157.7,156.1,150.4,125.0,104.4,69.6,48.6,41.2,33.6,31.9,30.2,20.1,13.9;MS m/z 359.20[M+H]+。
反式-4-((2-(丁基氨基)-5-(5-((4-甲基哌嗪-1-基)甲基)呋喃-2-基)嘧啶
-4-基)氨基)环己醇
在室温下,搅拌1-甲基哌嗪(29.3mg,0.29mmol)、5-(2-(丁基氨基)-4-((反式-4-羟基环己基)氨基)嘧啶-5-基)呋喃-2-甲醛(35mg,0.098mmol)、乙酸(28mg,0.29mmol)和三乙酰氧基硼氢化钠(62.1mg,0.29mmol)在DCM(10mL)中的混合物2小时,然后用NaHCO3(饱和的)淬灭,并用DCM(3x)萃取。将合并的有机层用水和盐水洗涤,干燥(Na2SO4)并浓缩。在HPLC上纯化剩余物,得到反式-4-((2-(丁基氨基)-5-(5-((4-甲基哌嗪-1-基)甲基)呋喃-2-基)嘧啶-4-基)氨基)环己醇(UNC2897A)(35.2mg,82%)。1H NMR(400MHz,CD3OD)δ7.82(s,1H),6.68(d,J=3.4Hz,1H),6.59(d,J=3.4Hz,1H),4.18–4.09(m,1H),3.99(s,2H),3.64–3.54(m,1H),3.54–3.42(m,2H),3.45–3.32(m,4H),3.18–2.94(m,4H),2.90(s,3H),2.19–1.97(m,4H),1.71–1.62(m,2H),1.59–1.31(m,6H),1.00(t,J=7.4Hz,3H);13C NMR(101MHz,CD3OD)δ160.6,160.2,149.5,146.2,139.4,117.5,114.6,112.7,109.6,68.7,52.5,48.8,42.0,40.8,33.3,30.9,29.0,19.7,12.7;MS m/z 443.35[M+H]+。
表4描述了使用合适的试剂,按照在实施例4中描述的方法(通用方法D)制备的化合物。
实施例5
反式-3-((2-(丁基氨基)-5-(吡啶-2-基)嘧啶-4-基)氨基)环丁醇
通用方法E:
反式-3-((2-(丁基氨基)-5-(吡啶-2-基)嘧啶-4-基)氨基)环丁醇
在微波照射下,于80℃下搅拌2,4-二氯-5-碘嘧啶(456mg,2mmol)和3-氨基环丁醇(183mg,2.1mmol)的iPrOH(6.0mL)溶液20分钟,然后加入BuNH2(1.0mL)。在微波照射下,于100℃下搅拌得到的反应混合物30分钟,然后用盐水淬灭并用CH2Cl2(3x)萃取。将合并的有机层干燥(Na2SO4)并浓缩。将剩余物溶于DMF/H2O(8.0mL/2.0mL)中。向该溶液中加入2-吡啶基三羟基硼酸锂(882mmol,6.0mmol)、溴化铜(57.4mg,0.40mmol)、碳酸钾(828mg,6.0mmol)和PdCl2(dppf)(164mg,0.20mmol)。在120℃下,加热反应混合物30分钟。然后,在将其冷却至室温之后,用EtOAc(15mL)稀释。使悬浮液过滤穿过薄的硅藻土垫料,用乙酸乙酯洗涤。将滤液用水(2x30mL)洗涤,干燥(MgSO4)并浓缩。在ISCO上纯化剩余物,得到反式-3-((2-(丁基氨基)-5-(吡啶-2-基)嘧啶-4-基)氨基)环丁醇(UNC2963A)(326mg,52%(经三步))。1H NMR(400MHz,CD3OD)δ8.66(d,J=5.1Hz,1H),8.27(s,1H),7.98(d,J=8.2Hz,1H),7.90(d,J=8.2Hz,1H),7.57–7.37(m,1H),4.77–4.64(m,1H),4.53–4.41(m,1H),3.75–3.55(m,1H),3.49(s,2H),2.43(t,J=6.2Hz,4H),1.64(dd,J=14.8,7.5Hz,2H),1.44(dd,J=15.0,7.4Hz,2H),0.98(t,J=7.4Hz,3H).MS m/z 314.0[M+1]+。
表5描述了使用合适的试剂,按照在实施例5中描述的方法(通用方法E)制备的化合物。
实施例6
反式-4-((2-(甲基氨基)-5-(吡啶-2-基)嘧啶-4-基)氨基)环己醇
通用方法F:
反式-4-((5-溴-2-(甲硫基)嘧啶-4-基)氨基)环己醇
在室温下,搅拌2,4-二氯-5-碘嘧啶(2.6g,10mmol)和4-氨基环己醇(1.27g,11mmol)的iPrOH(60mL)溶液并过夜,然后用CH2Cl2稀释,并用盐水洗涤。将有机层干燥(Na2SO4)并浓缩。在ISCO上纯化剩余物,得到呈白色固体的反式-4-((5-溴-2-(甲硫基)嘧啶-4-基)氨基)环己醇(3.19g,>99%)。1H NMR(400MHz,CDCl3)δ8.04(s,1H),5.10(d,J=7.2Hz,1H),3.97(dtd,J=11.1,7.3,3.8Hz,1H),3.74–3.59(m,1H),2.13(d,J=12.4Hz,2H),2.02(d,J=12.4Hz,2H),1.58(d,J=25.3Hz,1H),1.44(ddd,J=23.2,12.9,3.2Hz,2H),1.30(ddd,J=24.2,12.8,3.1Hz,2H).13CNMR(101MHz,cdcl3)δ170.33(s),156.85(s),155.07(s),99.73(s),69.70(s),49.15(s),33.78(s),30.41(s),14.34(d,J=3.7Hz).LC-MS(ESI+):tR=5.104min,MS m/z 318.0[M+1]+;
反式-4-((2-(甲硫基)-5-(吡啶-2-基)嘧啶-4-基)氨基)环己醇
在室温下,向反式-4-((5-溴-2-(甲硫基)嘧啶-4-基)氨基)环己醇(2.18g,6.36mmol)在DMF/H2O(16.0mL/4.0mL)混合物的溶液中加入2-吡啶基三羟基硼酸锂(2.80g,19.1mmol)、溴化铜(183mg,1.27mmol)、碳酸钾(2.63g,19.1mmol)和PdCl2(dppf)(519mg,0.64mmol)。在120℃下,加热反应混合物30分钟,然后冷却至室温,之后用EtOAc(15mL)稀释。将得到的悬浮液过滤穿过薄的硅藻土垫料,用乙酸乙酯洗涤。将滤液用水(2x30mL)洗涤,干燥(MgSO4)并浓缩。通过快速色谱纯化剩余物,得到呈白色固体的反式-4-((2-(甲硫基)-5-(吡啶-2-基)嘧啶-4-基)氨基)环己醇(1.06g,53%)。1H NMR(400MHz,CD3OD)δ8.58–8.49(m,1H),8.43(s,1H),7.85(ddd,J=10.0,9.6,5.0Hz,2H),7.34–7.22(m,1H),4.09(dd,J=9.4,5.3Hz,1H),3.69–3.58(m,1H),2.52(s,3H),2.19–2.11(m,2H),1.98(dd,J=10.7,7.7Hz,2H),1.50–1.32(m,3H).13C NMR(101MHz,cd3od)δ170.96(s),158.47(s),154.56(s),152.22(s),147.21(s),137.25(s),121.55(s),119.78(s),108.55(s),68.89(s),33.02(s),29.75(s),12.66(d,J=3.6Hz)。
反式-4-((2-(甲基氨基)-5-(吡啶-2-基)嘧啶-4-基)氨基)环己醇
向反式-4-((2-(甲硫基)-5-(吡啶-2-基)嘧啶-4-基)氨基)环己醇(95mg,0.5mmol)的THF(5mL)溶液中加入mCPBA(130mg,0.75mmol)。在室温下,搅拌反应混合物2小时。然后,加入甲胺(2mmol)。在微波照射下,于150℃下加热反应混合物30分钟。在减压下除去溶剂。在ISCO上纯化剩余物,得到呈浅褐色固体的反式-4-((2-(甲基氨基)-5-(吡啶-2-基)嘧啶-4-基)氨基)环己醇(UNC3122A)(120mg,80%)。1H NMR(400MHz,CD3OD)δ8.73(d,J=4.5Hz,1H),8.27–8.15(m,2H),8.00(d,J=8.1Hz,1H),7.71–7.58(m,1H),4.18(s,1H),3.68–3.56(m,1H),3.05(s,3H),2.12(s,2H),2.01(d,J=10.6Hz,2H),1.46(dd,J=23.8,12.8Hz,4H).LC-MS(ESI+):tR=3.914min,MS m/z 300.0[M+1]+;
表6描述了使用合适的试剂,按照在实施例6中描述的方法(通用方法F)制备的化合物。
实施例7
反式-4-((2-(丁基氨基)-5-(4-(吗啉代甲基)吡啶-2-基)嘧啶-4-基)氨基)
环己醇
通用方法G:
(2-氯-4-((反式-4-羟基环己基)氨基)嘧啶-5-基)硼酸
在0℃下,将5-溴-2,4-二氯嘧啶(51g,223.8mmol)溶于无水二噁烷(150mL)中。然后,分几批加入反式-4-氨基环己醇(26.3g,228.3mmol),接着加入DIEA(37.6g,290.9mmol)。在0℃下,搅拌得到的混合物5小时,并在室温下搅拌3小时,用水(100mL)淬灭并用EtOAc(3x)萃取。将合并的有机层干燥(Na2SO4)并浓缩。从EtOAc/己烷的混合物重结晶剩余物,得到呈白色固体的反式-4-((5-溴-2-氯嘧啶-4-基)氨基)环己醇(55g),其用于下一步中而无需进一步纯化。
使反式-4-((5-溴-2-氯嘧啶-4-基)氨基)环己醇(5.50g,17.94mmol)、双(频哪醇合(pinacolato))二硼(6.83g,26.90mmol)、Pd(dppf)2Cl2(732mg,0.90mmol)和KOAc(5.28g,53.80mmol)在无水二噁烷(125mL)中的混合物充分脱气,并在N2气氛下于90℃下加热75分钟。然后,使该热混合物过滤穿过硅藻土垫料且浓缩,在ISCO上纯化剩余物(以除去大部分未反应的反式-4-((5-溴-2-氯嘧啶-4-基)氨基)环己醇),接着在反相ISCO(洗脱溶剂含有0.1%TFA)上进一步纯化,得到2-氯-4-((反式-4-羟基环己基)氨基)嘧啶-5-基)硼酸(1.84g,经3步36%)。1H NMR(400MHz,cd3od)δ7.98(s,1H),3.99–3.90(m,1H),3.64–3.56(m,1H),2.07–2.00(m,2H),2.00–1.91(m,2H),1.48–1.34(m,4H);MS m/z 272.30[M+H]+。
反式-4-((2-(丁基氨基)-5-(4-(吗啉代甲基)吡啶-2-基)嘧啶-4-基)氨基)
环己醇
使在10mL微波管中的(2-氯-4-((反式-4-羟基环己基)氨基)嘧啶-5-基)硼酸(45mg,0.166mmol)、4-((2-溴吡啶-4-基)甲基)吗啉(85.2mg,0.33mmol)、Pd2(dba)3(7.6mg,0.008mmol)、PCy3(6.9mg,0.025mmol)、K3PO4(0.33mL,在去离子水中1M溶液)和丁胺(50mg,0.66mmol)的混合物脱气,并充满N2(3X)。在微波照射下,于120℃下加热得到的混合物20分钟,然后用水淬灭,并用EtOAc(3x)萃取。将合并的有机层干燥(Na2SO4)并浓缩。在HPLC上纯化剩余物,得到呈白色固体的反式-4-((2-(丁基氨基)-5-(4-(吗啉代甲基)吡啶-2-基)嘧啶-4-基)氨基)环己醇(UNC3015A)(54.5mg,75%)。1H NMR(400MHz,cd3od)δ8.72–8.66(m,1H),8.42–8.34(m,1H),8.04(s,1H),7.52–7.48(m,1H),4.43(s,2H),4.19–4.09(m,1H),3.93–3.83(m,3H),3.70–3.60(m,1H),3.56–3.42(m,2H),3.37–3.30(m,3H),2.20–2.11(m,2H),2.07–1.95(m,2H),1.70–1.62(m,2H),1.55–1.36(m,5H),0.99(t,J=7.4Hz,3H);MS m/z 441.30[M+H]+。
表8描述了可以使用合适的试剂,同样可按照在实施例7中描述的方法(通用方法G)制备的化合物。
前述为本发明的示例,不应当被看作限制本发明。本发明由下述权利要求书定义,权利要求的等同物也包括于其中。
Claims (20)
1.式I或式II的化合物或其药学上可接受盐:
其中∶
环A为5-或6-元杂芳基;
虚线为任选的双键;
X为N或O;
Y为环A中任何合适位置的碳原子或S或N杂原子;
R1为-R5R6,其中R5为共价键、C1至C3烷基或连接基基团,且R6为环烷基、杂环烷基、芳基、杂芳基、烷基环烷基、烷基杂环烷基、烷基芳基、烷基杂芳基或烷基,并且其中R6任选地被独立选择的极性基团取代一次、两次或三次;
R2为–R7R8,其中R7为共价键或C1至C3烷基,且R8为环烷基、杂环烷基、芳基、杂芳基或烷基,其中R8任选地被独立选择的极性基团取代一至三次;
R3选自H、烷基、芳基、芳基烷基;环烷基烷基、杂环烷基烷基、杂芳基烷基、和烷氧基烷基,其中每个任选地被独立选择的极性基团取代一至三次;
R4为H、低级烷基、卤素或低级烷氧基。
2.权利要求1的化合物,其中R5为共价键。
3.权利要求1的化合物,其中R5为C1至C3亚烷基。
4.权利要求1的化合物,其中R5为–CH2-。
5.权利要求1至4的化合物,其中R7为共价键。
6.权利要求1至4的化合物,其中R7为C1至C3亚烷基。
7.权利要求1至4的化合物,其中R7为–CH2-。
8.权利要求1至7的化合物,其中R6为苯基、哌啶基、C1-C8烷基或C3-C8环烷基,所述苯基、哌啶基、烷基或环烷基烷基为未取代的或被磺酰基、卤素、氨基、硝基、烷基、烷氧基、卤代烷基、环烷基、杂环烷基、芳基或杂芳基取代1-3次。
9.权利要求1至8的化合物,其中R8为C1-C8烷基或环己基,所述烷基或环己基为未取代的或被羟基或氨基取代1至3次。
10.权利要求1至9的化合物,其中R3为C1-C8烷基、C3-C8环烷基、C4-C12环烷基烷基、C3-C8杂环烷基、C4-C12杂环烷基烷基、C4-C12芳基烷基、C4-C12杂芳基烷基,其中每个为未取代的或被羟基、卤素或烷氧基取代1至3次。
11.权利要求1至10的化合物,其中R2为:
其中X为OH或NH2,且n为0或1。
12.权利要求1至11的化合物,其中R4为H。
13.权利要求1的化合物,其中所述化合物具有如下结构:
或其药学上可接受盐。
14.权利要求1至12的化合物,其中所述化合物具有结构:
15.权利要求1的化合物,其中所述化合物具有结构:
或其药学上可接受盐。
16.组合物,其包括在药学上可接受载体中的权利要求1至15的化合物。
17.一种在有需要的受试者中治疗癌症的方法,包括向所述受试者给药有效地治疗所述癌症量的权利要求1至15的化合物。
18.权利要求17的方法,其中所述癌症选自髓性白血病、成淋巴细胞白血病、黑素瘤、乳腺癌、肺癌、结肠癌、肝癌、胃癌、肾癌、卵巢癌、子宫癌、和脑癌。
19.权利要求1至15的化合物,用于治疗癌症或用于制备治疗癌症的药物。
20.权利要求19的化合物,其中所述癌症选自髓性白血病、成淋巴细胞白血病、黑素瘤、乳腺癌、肺癌、结肠癌、肝癌、胃癌、肾癌、卵巢癌、子宫癌和脑癌。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261650000P | 2012-05-22 | 2012-05-22 | |
US61/650,000 | 2012-05-22 | ||
PCT/US2013/042033 WO2013177168A1 (en) | 2012-05-22 | 2013-05-21 | Pyrimidine compounds for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104302627A true CN104302627A (zh) | 2015-01-21 |
Family
ID=49624289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380025291.3A Pending CN104302627A (zh) | 2012-05-22 | 2013-05-21 | 用于治疗癌症的嘧啶化合物 |
Country Status (14)
Country | Link |
---|---|
US (1) | US9567326B2 (zh) |
EP (1) | EP2852579A4 (zh) |
JP (1) | JP2015517574A (zh) |
KR (1) | KR20150018789A (zh) |
CN (1) | CN104302627A (zh) |
AU (1) | AU2013266438B2 (zh) |
BR (1) | BR112014028424A2 (zh) |
CA (1) | CA2873878A1 (zh) |
HK (1) | HK1206338A1 (zh) |
IL (1) | IL235726A0 (zh) |
IN (1) | IN2014DN09610A (zh) |
MX (1) | MX2014013632A (zh) |
RU (1) | RU2014145121A (zh) |
WO (1) | WO2013177168A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106749173A (zh) * | 2016-11-25 | 2017-05-31 | 吉林化工学院 | 一种嘧啶联吡啶类化合物的制备方法 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2571361A4 (en) | 2010-05-19 | 2013-11-13 | Univ North Carolina | PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
JP2014532060A (ja) | 2011-10-03 | 2014-12-04 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 癌を治療するためのピロロピリミジン化合物 |
IN2014DN09610A (zh) | 2012-05-22 | 2015-07-31 | Univ North Carolina | |
US9598440B2 (en) | 2012-10-08 | 2017-03-21 | Merck Sharp & Dohme Corp. | Inhibitors of IRAK4 activity |
WO2014062774A1 (en) | 2012-10-17 | 2014-04-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
WO2014085225A1 (en) | 2012-11-27 | 2014-06-05 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
CN104926801B (zh) | 2014-03-22 | 2019-06-04 | 浙江大学 | 取代氮杂环类衍生物、含其的药物组合物及其在抗肿瘤中的应用 |
CA2945129A1 (en) | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Mertk-specific pyrrolopyrimidine compounds |
US10526309B2 (en) | 2015-10-02 | 2020-01-07 | The University Of North Carolina At Chapel Hill | Pan-TAM inhibitors and Mer/Axl dual inhibitors |
US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
WO2018005356A1 (en) | 2016-06-27 | 2018-01-04 | Rigel Pharmaceuticals, Inc. | 2,4-diamino-pyrimidine compounds and method for making and using the compounds |
US11053225B2 (en) | 2017-05-02 | 2021-07-06 | Korea Research Institute Of Chemical Technology | Pyrimidine derivative compound, optical isomer thereof, or pharmaceutically acceptable salt thereof, and composition for preventing or treating Tyro 3 related disease comprising same as active ingredient |
EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN DEGRADATION |
WO2022059996A1 (ko) * | 2020-09-15 | 2022-03-24 | 서울대학교 기술지주 주식회사 | 혈액 순환 미세체외소체 매개 암 치료용 조성물 |
KR102616469B1 (ko) * | 2020-09-15 | 2023-12-28 | 주식회사 유엔에스바이오 | 혈액 순환 미세체외소체 매개 암 치료용 조성물 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005095382A1 (ja) * | 2004-03-30 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | 抗腫瘍剤 |
WO2007032445A1 (ja) * | 2005-09-16 | 2007-03-22 | Kyowa Hakko Kogyo Co., Ltd. | タンパク質キナーゼ阻害剤 |
CN101031558A (zh) * | 2004-09-30 | 2007-09-05 | 泰博特克药品有限公司 | 抑制人类免疫缺陷病毒的5-杂环基嘧啶 |
CN101321751A (zh) * | 2005-09-30 | 2008-12-10 | 布里斯托尔-迈尔斯·斯奎布公司 | Met激酶抑制剂 |
WO2011065800A2 (ko) * | 2009-11-30 | 2011-06-03 | 주식회사 오스코텍 | 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물 |
WO2011090760A1 (en) * | 2009-12-29 | 2011-07-28 | Avila Therapeutics, Inc. | Heteroaryl compounds and uses thereof |
WO2012053606A1 (ja) * | 2010-10-22 | 2012-04-26 | アステラス製薬株式会社 | アリールアミノヘテロ環カルボキサミド化合物 |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH549339A (de) * | 1971-05-12 | 1974-05-31 | Ciba Geigy Ag | Herbizides mittel. |
US5958930A (en) | 1991-04-08 | 1999-09-28 | Duquesne University Of The Holy Ghost | Pyrrolo pyrimidine and furo pyrimidine derivatives |
WO1997049706A1 (en) | 1996-06-25 | 1997-12-31 | Novartis Ag | SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF |
US20080248046A1 (en) | 1997-03-17 | 2008-10-09 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
CN1657523A (zh) * | 2000-04-28 | 2005-08-24 | 田边制药株式会社 | 环状化合物 |
GB0016877D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
WO2003029209A2 (en) | 2001-10-02 | 2003-04-10 | Smithkline Beecham Corporation | Chemical compounds |
WO2004002964A1 (ja) * | 2002-06-28 | 2004-01-08 | Yamanouchi Pharmaceutical Co., Ltd. | ジアミノピリミジンカルボキサミド誘導体 |
DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
ATE389653T1 (de) | 2003-05-28 | 2008-04-15 | Univ Siena | 4-substituierte derivate von pyrazolo 3,4-d pyrimidin und deren verwendungen |
US7504396B2 (en) * | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
BRPI0414533A (pt) | 2003-09-18 | 2006-11-07 | Conforma Therapeutics Corp | composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90 |
CA2554201C (en) | 2004-01-21 | 2015-04-14 | Emory University | Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection |
JP2007520559A (ja) | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
BRPI0507668A (pt) | 2004-02-14 | 2007-07-17 | Irm Llc | compostos e composições como inibidores de proteìna cinase |
EP1732541A4 (en) | 2004-04-07 | 2008-03-05 | Takeda Pharmaceutical | CYCLIC COMPOUNDS |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
WO2006042102A2 (en) | 2004-10-05 | 2006-04-20 | Neurogen Corporation | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
EP1710246A1 (en) | 2005-04-08 | 2006-10-11 | Schering Aktiengesellschaft | Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer |
WO2007035963A2 (en) | 2005-09-23 | 2007-03-29 | Conforma Therapeutics Corporation | Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors |
US7547782B2 (en) * | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
EP1940847A2 (en) | 2005-10-06 | 2008-07-09 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
SG177194A1 (en) | 2005-12-08 | 2012-01-30 | Medarex Inc | Human monoclonal antibodies to protein tyrosine kinase 7 (ptk7) and methods for using anti-ptk7 antibodies |
WO2007075554A2 (en) | 2005-12-19 | 2007-07-05 | Osi Pharmaceuticals, Inc. | Combination of igfr inhibitor and anti-cancer agent |
EP1803723A1 (de) | 2006-01-03 | 2007-07-04 | Bayer Schering Pharma Aktiengesellschaft | (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs |
CA2645958C (en) | 2006-03-30 | 2014-11-04 | Tibotec Pharmaceuticals Ltd. | Hiv inhibiting 5-amido substituted pyrimidines |
JP2009535393A (ja) | 2006-05-01 | 2009-10-01 | ファイザー・プロダクツ・インク | 置換2−アミノ縮合複素環式化合物 |
GB0610242D0 (en) | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
TWI398252B (zh) | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
EP2133095A4 (en) * | 2007-03-05 | 2012-09-26 | Kyowa Hakko Kirin Co Ltd | PHARMACEUTICAL COMPOSITION |
AU2008296479A1 (en) | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
KR20100090772A (ko) | 2007-10-12 | 2010-08-17 | 인게니움 파르마코이티칼스 게엠베하 | 단백질 키나제 억제제 |
CA2960659C (en) | 2007-11-09 | 2021-07-13 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors |
NZ624345A (en) * | 2008-06-27 | 2016-07-29 | Celgene Avilomics Res Inc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US8399206B2 (en) | 2008-07-10 | 2013-03-19 | Nodality, Inc. | Methods for diagnosis, prognosis and methods of treatment |
WO2010014755A1 (en) | 2008-07-29 | 2010-02-04 | The Regents Of The University Of Colorado | Methods and compounds for enhancing anti-cancer therapy |
US8569466B2 (en) | 2008-09-10 | 2013-10-29 | Nnochiri Ekwuribe | Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancers |
US20100137313A1 (en) * | 2008-10-03 | 2010-06-03 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
GB0819105D0 (en) | 2008-10-17 | 2008-11-26 | Chroma Therapeutics Ltd | Pyrrolo-pyrimidine compounds |
WO2010068863A2 (en) | 2008-12-12 | 2010-06-17 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
WO2010085597A1 (en) | 2009-01-23 | 2010-07-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
TW201102391A (en) | 2009-03-31 | 2011-01-16 | Biogen Idec Inc | Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use |
UA107791C2 (en) | 2009-05-05 | 2015-02-25 | Dow Agrosciences Llc | Pesticidal compositions |
US8367689B2 (en) * | 2009-05-06 | 2013-02-05 | Portola Pharmaceuticals, Inc. | Inhibitors of JAK |
EP3381937A3 (en) | 2009-08-13 | 2018-10-31 | The Johns Hopkins University | Methods of modulating immune function |
MX2012002997A (es) | 2009-09-10 | 2012-08-01 | Novartis Ag | Derivados de eter de los heteroarilos biciclicos. |
US9433621B2 (en) | 2010-02-18 | 2016-09-06 | Merck Sharp & Dohme Corp. | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
GB201004311D0 (en) | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
EP2560488B1 (en) | 2010-04-23 | 2015-10-28 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
EP2571361A4 (en) | 2010-05-19 | 2013-11-13 | Univ North Carolina | PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
KR101817221B1 (ko) | 2010-11-18 | 2018-01-10 | 카시나 라일라 이노바 파마슈티칼스 프라이빗 리미티드 | 치환된 4-(셀레노펜-2(또는 3)-일아미노)피리미딘 화합물 및 이의 사용방법 |
US8362023B2 (en) | 2011-01-19 | 2013-01-29 | Hoffmann-La Roche Inc. | Pyrazolo pyrimidines |
US8889684B2 (en) | 2011-02-02 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
US9376438B2 (en) | 2011-05-17 | 2016-06-28 | Principia Biopharma, Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
WO2013032591A1 (en) * | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
CN103814030A (zh) | 2011-09-22 | 2014-05-21 | 辉瑞大药厂 | 吡咯并嘧啶及嘌呤衍生物 |
JP2014532060A (ja) | 2011-10-03 | 2014-12-04 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 癌を治療するためのピロロピリミジン化合物 |
JP2015509943A (ja) | 2012-02-21 | 2015-04-02 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ウイルス侵入補助因子としてのtamレセプター |
EP2840080B1 (en) * | 2012-04-17 | 2017-12-06 | FUJIFILM Corporation | Nitrogen-containing heterocyclic compound or salt thereof |
EP2838898B1 (en) | 2012-04-20 | 2017-01-18 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
IN2014DN09610A (zh) | 2012-05-22 | 2015-07-31 | Univ North Carolina | |
WO2014062774A1 (en) | 2012-10-17 | 2014-04-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
WO2014085225A1 (en) | 2012-11-27 | 2014-06-05 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
WO2015153978A1 (en) | 2014-04-04 | 2015-10-08 | The University Of North Carolina At Chapel Hill | Methods for the treatment of tumors |
CA2945129A1 (en) | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Mertk-specific pyrrolopyrimidine compounds |
-
2013
- 2013-05-21 IN IN9610DEN2014 patent/IN2014DN09610A/en unknown
- 2013-05-21 JP JP2015514115A patent/JP2015517574A/ja active Pending
- 2013-05-21 RU RU2014145121A patent/RU2014145121A/ru not_active Application Discontinuation
- 2013-05-21 MX MX2014013632A patent/MX2014013632A/es unknown
- 2013-05-21 CN CN201380025291.3A patent/CN104302627A/zh active Pending
- 2013-05-21 CA CA2873878A patent/CA2873878A1/en not_active Abandoned
- 2013-05-21 AU AU2013266438A patent/AU2013266438B2/en not_active Expired - Fee Related
- 2013-05-21 US US14/384,789 patent/US9567326B2/en active Active
- 2013-05-21 BR BR112014028424A patent/BR112014028424A2/pt not_active Application Discontinuation
- 2013-05-21 WO PCT/US2013/042033 patent/WO2013177168A1/en active Application Filing
- 2013-05-21 KR KR1020147032028A patent/KR20150018789A/ko not_active Application Discontinuation
- 2013-05-21 EP EP13793925.2A patent/EP2852579A4/en not_active Withdrawn
-
2014
- 2014-11-16 IL IL235726A patent/IL235726A0/en unknown
-
2015
- 2015-07-20 HK HK15106878.7A patent/HK1206338A1/zh unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005095382A1 (ja) * | 2004-03-30 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | 抗腫瘍剤 |
CN101031558A (zh) * | 2004-09-30 | 2007-09-05 | 泰博特克药品有限公司 | 抑制人类免疫缺陷病毒的5-杂环基嘧啶 |
WO2007032445A1 (ja) * | 2005-09-16 | 2007-03-22 | Kyowa Hakko Kogyo Co., Ltd. | タンパク質キナーゼ阻害剤 |
CN101321751A (zh) * | 2005-09-30 | 2008-12-10 | 布里斯托尔-迈尔斯·斯奎布公司 | Met激酶抑制剂 |
WO2011065800A2 (ko) * | 2009-11-30 | 2011-06-03 | 주식회사 오스코텍 | 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물 |
WO2011090760A1 (en) * | 2009-12-29 | 2011-07-28 | Avila Therapeutics, Inc. | Heteroaryl compounds and uses thereof |
WO2012053606A1 (ja) * | 2010-10-22 | 2012-04-26 | アステラス製薬株式会社 | アリールアミノヘテロ環カルボキサミド化合物 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106749173A (zh) * | 2016-11-25 | 2017-05-31 | 吉林化工学院 | 一种嘧啶联吡啶类化合物的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
IL235726A0 (en) | 2015-02-01 |
RU2014145121A (ru) | 2016-07-10 |
EP2852579A4 (en) | 2015-12-30 |
CA2873878A1 (en) | 2013-11-28 |
AU2013266438B2 (en) | 2017-09-07 |
HK1206338A1 (zh) | 2016-01-08 |
US9567326B2 (en) | 2017-02-14 |
EP2852579A1 (en) | 2015-04-01 |
AU2013266438A1 (en) | 2014-12-04 |
BR112014028424A2 (pt) | 2018-04-24 |
WO2013177168A1 (en) | 2013-11-28 |
US20150038481A1 (en) | 2015-02-05 |
KR20150018789A (ko) | 2015-02-24 |
IN2014DN09610A (zh) | 2015-07-31 |
JP2015517574A (ja) | 2015-06-22 |
MX2014013632A (es) | 2015-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104302627A (zh) | 用于治疗癌症的嘧啶化合物 | |
CN103958510A (zh) | 用于治疗癌症的吡咯并嘧啶化合物 | |
CN106854205B (zh) | 流感病毒复制抑制剂及其使用方法和用途 | |
CN103261167B (zh) | 取代的6,6-稠合含氮杂环化合物及其用途 | |
CN109641868A (zh) | 流感病毒复制抑制剂及其使用方法和用途 | |
CN107787323A (zh) | 用于抑制shp2活性的化合物和组合物 | |
CN109369640A (zh) | 一种二氢异喹啉类化合物的制备方法 | |
CN105899493A (zh) | 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物 | |
CN104650068A (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
RU2002130252A (ru) | Замещенные амиды бензойной кислоты и их применение для подавления ангиогенеза | |
CN104507933A (zh) | 氨基喹唑啉和吡啶并嘧啶衍生物 | |
EP2925752A1 (en) | Pyrimidine compounds for the treatment of cancer | |
CN108473478A (zh) | TBK/IKKε抑制剂化合物及其用途 | |
CN108218873A (zh) | 流感病毒复制抑制剂及其用途 | |
CN107759571A (zh) | 流感病毒复制抑制剂及其使用方法和用途 | |
ES2734479T3 (es) | Medios y métodos para tratar tumores sólidos | |
CN101796056A (zh) | c-MET的杂环抑制剂及其用途 | |
CN104725356A (zh) | 氮杂环衍生物及其在药物中的应用 | |
CN105980349A (zh) | 苯甲酰胺和烟酰胺化合物及其使用方法 | |
CN108727369A (zh) | 流感病毒复制抑制剂及其用途 | |
WO2022017408A1 (zh) | 芳胺类衍生物及其制备方法和医药用途 | |
JPS625975A (ja) | フロセミド誘導体 | |
WO2021147940A1 (zh) | 一种pd-1/pd-l1抑制剂及其制备方法和用途 | |
JPH05213755A (ja) | 肝臓障害治療薬 | |
CN109651341A (zh) | 二吗啉氰基嘧(吡)啶类衍生物及作为抗肿瘤药物应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1206338 Country of ref document: HK |
|
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150121 |
|
WD01 | Invention patent application deemed withdrawn after publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1206338 Country of ref document: HK |